Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4229 trials
Conditions Asthma in Children, Directly Observed Th...
Phase NA
Enrollment 400
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

Children with asthma from communities that experience health inequities frequently do not receive guideline-based asthma care, and as a result, account for a disproportionate percentage of asthma exacerbations, emergency department visits, and hospitalizations. Project ASTHMA (Aligning with Schools To Help Manage Asthma) tests the effectiveness of school-based health centers as a delivery model to improve health outcomes by providing children with guideline-based asthma assessments and preventive medication management, directly observed therapy of their preventive medication to support adherence, and self-management support. If successful, this multicomponent intervention will represent a cost effective and sustainable model to reduce asthma morbidity in historically marginalized communities, and has the potential to impact communities throughout the United States where over 2,500 school-based health centers operate.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Health Services Research Masking/blinding: None

Interventions / Regimen

  • Other: APP assessment and management of asthma — APPs will be trained to follow NIH guidelines for assessment and management of asthma, and to apply their knowledge to the care of the students. Students will also receive DOT of the morning dose of their controller medication.

Primary Outcomes

  • Asthma exacerbations (from 1 month after enrollment to the end of the school year for 1 school year; to be assessed after the end of the school year.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-09-27
Completion: 2028-04-30
Eligibility
Age: 4 Years – 13 Years
Sex: ALL
Volunteers: false
Enrollment: 400 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: State University of New York at Buffalo
Collaborators: National Institute on Minority Health and Health Disparities (NIMHD)
Contact Information
Study Contact:
Lucy CY Holmes, MD, MPH
716-323-0034
LHolmes@upa.chob.edu
Deanna Hamilton, MSEd
716-323-0060
DeHamilton@upa.chob.edu
Lucy Holmes, MD, MPH
716-323-0034
LHolmes@upa.chob.edu
University at Buffalo, Department of Pediatrics
Interventions
  • Other: APP assessment and management of asthma — APPs will be trained to follow NIH guidelines for assessment and management of asthma, and to apply their knowledge to the care of the students. Students will also receive DOT of the morning dose of their controller medication.
Study Locations (1 sites)
University at Buffalo, Department of Pediatrics, Buffalo, New York 14203 United States
Eligibility Criteria
Inclusion Criteria: * uncontrolled asthma Exclusion Criteria: * other chronic lung disease such as cystic fibrosis
Conditions Asthma (Diagnosis)
Phase PHASE3
Enrollment 416
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

A multicenter, randomized, double-blind, active-controlled, parallel-group Phase III clinical study comparing the efficacy and safety of Beclometasone Dipropionate and Formoterol Inhalation Aerosol versus FOSTER® in patients with asthma. The purpose of this study is to compare the efficacy and safety of the Beclomethasone Dipropionate and Formoterol Fumarate inhalation aerosol (manufactured by Lunan Better Pharmaceutical Co., Ltd.) with FOSTER® in the treatment of patients with asthma.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Drug: Beclometasone Dipropionate and Formoterol Inhalation Aerosol — Beclometasone Dipropionate and Formoterol Inhalation Aerosol was administered by oral inhalation at a dose of 2 actuations twice daily (morning and evening) for 4 consecutive weeks.
  • Drug: FOSTER® — Beclometasone Dipropionate and Formoterol Inhalation Aerosol was administered by oral inhalation at a dose of 2 actuations twice daily (morning and evening) for 4 consecutive weeks.

Primary Outcomes

  • Change from baseline in forced expiratory volume in 1 second (FEV1) at Week 4 (Baseline to Week 4.(at the end of the 4-week treatment period))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2026-06-08
Completion: 2028-06
Eligibility
Age: 18 Years – 75 Years
Sex: ALL
Volunteers: false
Enrollment: 416 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Lunan Better Pharmaceutical Co., LTD.
Contact Information
Study Contact:
Mei Ling Jin
021-31587861
MLjin118@163.com
Zhenju Song
021-31587861
Song.zhenju@zs-hospital.sh.cn
Meiling Jin
021-31587861
MLjin118@163.com
Zhongshan Hospital, Fudan University
Interventions
  • Drug: Beclometasone Dipropionate and Formoterol Inhalation Aerosol — Beclometasone Dipropionate and Formoterol Inhalation Aerosol was administered by oral inhalation at a dose of 2 actuations twice daily (morning and evening) for 4 consecutive weeks.
  • Drug: FOSTER® — Beclometasone Dipropionate and Formoterol Inhalation Aerosol was administered by oral inhalation at a dose of 2 actuations twice daily (morning and evening) for 4 consecutive weeks.
Study Locations (1 sites)
Zhongshan Hospital, Fudan University, Shanghai, Shanghai Municipality China
Eligibility Criteria
Inclusion Criteria: 1. Male or female aged ≥18 and ≤75 years. 2. Clinically diagnosed with bronchial asthma for at least 3 months at screening (with traceable diagnostic evidence and medical records), and the diagnosis has been confirmed according to the Guidelines for the Prevention and Management of Bronchial Asthma, meeting the following criteria: a) Positive objective test for variable airflow limitation (i.e., meeting any one of the following): (i) Positive bronchodilator reversibility test (i.e., an increase in FEV₁ of ≥12% and an absolute increase of ≥200 mL from pre-bronchodilator values after inhalation of a bronchodilator; or an increase in FEV₁ of ≥12% and an absolute increase of ≥200 mL from baseline after 4 weeks of anti-inflammatory therapy with an inhaled corticosteroid, excluding respiratory tract infections); or (ii) Positive bronchial provocation test: commonly using methacholine or histamine as the inhaled provocative agent, with a positive result defined as a ≥20% decrease in FEV₁ after inhalation, indicating airway hyperresponsiveness. (A positive result from any confirmed objective test for variable airflow limitation performed within 1 year prior to signing the ICF is acceptable; if not available, a positive bronchial provocation or bronchodilator reversibility test must be met at screening.) b) Pulmonary function test: FEV₁ ≥40% of predicted value. 3. Within at least 4 weeks prior to signing the ICF, the subject has been on a stable daily dose of an inhaled corticosteroid (ICS) with "as-needed" short-acting β₂-agonist (SABA) use but asthma is not well controlled (ACQ-5 ≥1.00), OR has been on a stable daily dose of an ICS plus a long-acting β₂-agonist (LABA) and asthma is well controlled (ACQ-5 \<1.00). 4. Subjects who use SABA or other reliever medications as needed before screening may be enrolled only if the investigator assesses that they can be switched to the unified rescue medication provided in this study. 5. Willing and able to comply with the protocol requirements and the investigator's instructions for pulmonary function tests, and, after training, able to correctly use the pressurized metered-dose inhaler (pMDI), peak flow meter, and complete the diary card records. 6. Willing to voluntarily participate in this study and sign the informed consent form after full informed consent. Exclusion Criteria: 1. Have intermittent asthma or asthma that occurs only upon occasional exposure to allergens or chemical sensitizers. 2. Have a history of life-threatening asthma (e.g., brittle asthma, admission to the intensive care unit due to an acute asthma exacerbation) within 1 year prior to screening. 3. Have other respiratory system diseases, including but not limited to allergic bronchopulmonary aspergillosis (ABPA), active tuberculosis, pneumonia, pneumothorax, idiopathic pulmonary fibrosis, clinically significant atelectasis, chronic obstructive pulmonary disease (COPD), bronchopulmonary dysplasia, chronic bronchitis, or other significant pulmonary abnormalities other than asthma (such as cystic fibrosis, bronchiectasis, or alpha-1 antitrypsin deficiency), and are considered by the investigator to be unsuitable for participation in this clinical study. 4. Have a respiratory tract infection of non-viral etiology, sinusitis, or otitis media within 4 weeks prior to screening. 5. Have a history of severe cardiovascular or cerebrovascular diseases, such as congestive heart failure of New York Heart Association (NYHA) class ≥II, unstable angina, coronary heart disease, myocardial infarction, stroke, etc., within 6 months prior to screening; have a prolonged QTc interval (QTc \>450 ms for males or \>470 ms for females, corrected using Fridericia's formula) or have ECG abnormalities that are assessed by the investigator as clinically significant and requiring pharmacological treatment; or have poorly controlled hypertension (systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg after adequate treatment). 6. Have oral candidiasis identified at screening. 7. Have laboratory test results meeting any of the following criteria: Liver function: alanine aminotransferase (ALT) \>2×ULN and/or aspartate aminotransferase (AST) \>2×ULN, and total bilirubin (TBIL) \>2×ULN; Renal function: serum creatinine \>1.5×ULN; Fasting blood glucose \>10 mmol/L or glycated hemoglobin (HbA1c) ≥8.0%; Serum potassium \<3.5 mmol/L. 8. Have received biological targeted therapy (including anti-IgE monoclonal antibodies such as omalizumab, anti-IL-5 monoclonal antibodies such as mepolizumab, anti-IL-5 receptor monoclonal antibodies such as benralizumab, or anti-IL-4 receptor monoclonal antibodies such as dupilumab) within 5 half-lives prior to entry into the run-in period. 9. Have experienced an asthma exacerbation requiring systemic corticosteroid treatment or have required oral corticosteroid therapy within 4 weeks prior to screening, or have other diseases that require long-term oral or intravenous corticosteroid therapy. 10. Have used beta-blockers (including eye drops), quinidine, disopyramide, procainamide, phenothiazines, monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants, or any other medications that may prolong the QTc interval and increase the risk of ventricular arrhythmias within 4 weeks prior to screening. 11. Have a history of drug abuse or alcohol abuse within 1 year prior to screening. 12. Are current smokers; have a smoking history of ≥10 pack-years (1 pack = 20 cigarettes); for those with a smoking history of \<10 pack-years, they must have stopped smoking for at least 6 months to be eligible for the study. 13. Have received treatment with any other investigational drug or device in another clinical trial within 3 months prior to screening. 14. Have a known intolerance to or contraindication to beta₂-agonists and/or inhaled corticosteroids, or are allergic to any component of the investigational products. 15. Are pregnant or breastfeeding; or are women of childbearing potential, or male subjects with partners of childbearing potential, who do not agree to use medically recognized effective contraceptive measures (such as an intrauterine device or condom) during the study and for 6 months after the last dose of the investigational product. 16. Meet any of the following conditions prior to randomization: 1. Run-in period compliance \<80% or \>120%; 2. Have an asthma exacerbation during the run-in period (including asthma-related serious adverse events, asthma worsening leading to hospitalization or emergency treatment, unscheduled visits resulting in changes in treatment, etc.); 3. Are considered by the investigator to be unsuitable for randomization.
Conditions Asthma in Children, Asthma Attack
Phase EARLY_PHASE1
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to identify whether early administration of magnesium sulfate in moderate asthma exacerbations can potentially avoid admission, decrease length of stay in the emergency department (ED), decrease length of stay (LOS) in the general hospital floor vs pediatric intensive care unit (PICU), and decrease the need for respiratory support.

Design

Study type: Interventional Phases: Early Phase1 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Drug: Magnesium Sulfate within the first hour — The experimental group will receive 40-50 mg/kg of IV magnesium sulfate will be given to the experimental group alongside the first line asthma therapies (ie inhaled beta agonists, IV steroids). This will be given with a 20 mL/kg normal saline bolus (max 1000 mL) to avoid possible hypotension. 15-19 kg: 750 mg 20-29 kg: 1000 mg 30-39 kg: 1500 mg \>40 kg: 2000 mg
  • Other: No Magnesium sulfate within the first hour — The control group will not receive IV magnesium sulfate within the first hour of treatment.

Primary Outcomes

  • Change in Length of Stay in Patients who receive IV Magnesium within the first hour (experimental group) vs control group (From initiation of therapy to discharge from the emergency department or admitting unit, up to 1 week)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: Recruiting
Start Date: 2023-11-30
Completion: 2025-05-31
Eligibility
Age: 5 Years – 17 Years
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Oklahoma
Principal Investigators:
  • Ryan McKee, MD (PRINCIPAL_INVESTIGATOR) - University of Oklahoma
Contact Information
Study Contact:
Ryan McKee, MD
4056308997
ryan-mckee@ouhsc.edu
Jaclyn Urquiola Sorzano, DO
7863906297
jaclyn-urquiola@ouhsc.edu
Ryan McKee, MD
405-271-2429
Ryan-McKee@ouhsc.edu
Oklahoma Children's Hospital
Interventions
  • Drug: Magnesium Sulfate within the first hour — The experimental group will receive 40-50 mg/kg of IV magnesium sulfate will be given to the experimental group alongside the first line asthma therapies (ie inhaled beta agonists, IV steroids). This will be given with a 20 mL/kg normal saline bolus (max 1000 mL) to avoid possible hypotension. 15-19 kg: 750 mg 20-29 kg: 1000 mg 30-39 kg: 1500 mg \>40 kg: 2000 mg
  • Other: No Magnesium sulfate within the first hour — The control group will not receive IV magnesium sulfate within the first hour of treatment.
Study Locations (1 sites)
Oklahoma Children's Hospital, Oklahoma City, Oklahoma 73104 United States
Eligibility Criteria
Inclusion Criteria: * Ages 5-17 years old * Presents to the ED with a respiratory score in the "Moderate" range (6 * Parent(s)/Caregiver(s) speak English Exclusion Criteria: * Patients with chronic medical conditions including chronic pulmonary disease (other than asthma), cerebral palsy, congenital heart disease, tracheostomy dependent, myasthenia gravis patients * Patients who are pregnant * Parent(s)/Caregiver(s) do not speak English
Conditions Immunological Disease, Autoimmune Diseas...
Phase Not Applicable
Enrollment 800
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

The study team plans to establish a bioregistry of patients receiving biologic therapy as part of their standard treatment at the Mount Sinai Therapeutic Infusion Center and affiliated practices. The study team will to apply state-of-the-art approaches to assessing and predicting immunological and clinical responses associated with these standards and prescribed treatments. The approach is twofold. The first component is to establish a robust and flexible biorepository and database that includes demographic, immunologic, exposure and clinical records, and can facilitate research across disciplines, and across other registries affiliated with Mount Sinai. The second component is to address specific key research questions focused on using novel diagnostics to increase the effectiveness of biologic treatment. Most patients will be recruited from the Mount Sinai Therapeutic Infusion Center (TIC), although others receiving infusions elsewhere or at home will be recruited from outpatient Sinai affiliated clinical practices.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Biologics and Clinical Immunology Registry (3 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2021-03-03
Completion: 2030-11
Eligibility
Age: 12 Years and older
Sex: ALL
Volunteers: false
Enrollment: 800 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Icahn School of Medicine at Mount Sinai
Principal Investigators:
  • Rachel Miller (PRINCIPAL_INVESTIGATOR) - Icahn School of Medicine
Contact Information
Study Contact:
Sarah Alvi
212-659-9416
Sarah.Alvi@mssm.edu
Sonia Parmar
973-944-8221
sonia.parmar@mssm.edu
Sarah Alvi
Sarah.Alvi@mssm.edu
Mount Sinai
Interventions
N/A
Study Locations (1 sites)
Mount Sinai, New York, New York 10029 United States
Eligibility Criteria
Inclusion Criteria: * Age 12 years and up. * Able to provide informed consent. * Medical care at Mount Sinai. * Receiving a biologic medication or immune modulator at Mount Sinai, or considered an appropriate negative control or comparison participant by the study team.
Conditions Allergic Rhinitis, Asthma (Diagnosis)
Phase PHASE4
Enrollment 40
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

STUDY DESIGN A single-center prospective before-and-after study evaluating the effect of Alutard SQ Dog in 40 men and women with moderate-to-severe dog allergy. Participants will serve as their own controls. STUDY OUTLINE The study will begin in the fall of 2026 and will be conducted over a one-year period. At baseline, participants will be asked to record their allergic symptoms, and assessments of lung function and nasal airflow will be performed. Blood samples will also be collected. Following the baseline assessments, participants will undergo allergen provocation by entering a facility containing dogs. After a 30-minute exposure to dogs, participants will again be asked to record their allergic symptoms and will undergo the same assessments performed at baseline. Allergen immunotherapy (AIT) with Alutard SQ Dog will then be initiated according to the standard treatment regimen and continued for one year. At the end of the treatment period, the same provocation procedure and assessments will be repeated. Participants will enter a facility containing dogs, followed by symptom recording and evaluation of lung function, nasal airflow, and relevant laboratory parameters.

Design

Study type: Interventional Phases: Phase4 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: ALK Alutard SQ Dog — The study is based on Swedish guidelines with an up-titration period of 13 weeks from 100 SQ to 100.000 SQ. The maximum dose of 100.000 SQ is the given every 6-8 weeks for 3 years.

Primary Outcomes

  • Total nasal symptom score (TNSS) (Patients will be exposed to dog allergen at baseline and again after one year of treatment with Alutard SQ dog. TNSS will be assessed at both occasions.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2026-08-01
Completion: 2027-12-01
Eligibility
Age: 18 Years – 50 Years
Sex: ALL
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Karolinska Institutet
Principal Investigators:
  • Lars Olaf Cardell (PRINCIPAL_INVESTIGATOR) - Karolinska Institutet, Division of ENT
Contact Information
Study Contact:
Carl Skröder, MD
+46 41055181
carl.skroder@ki.com
Lars Olaf Cardell, Professor
lars-olaf.cardell@ki.se
Franziska Nordström, MD
+46704447341
franziska.nordstrom@skane.se
Lund University Hospital
Interventions
  • Drug: ALK Alutard SQ Dog — The study is based on Swedish guidelines with an up-titration period of 13 weeks from 100 SQ to 100.000 SQ. The maximum dose of 100.000 SQ is the given every 6-8 weeks for 3 years.
Study Locations (2 sites)
Lund University Hospital, Lund, Skåne County 23152 Sweden
Trelleborg Hospital, Trelleborg, Skåne County 23152 Sweden
Eligibility Criteria
Inclusion Criteria The subject has provided written informed consent to participate in the study. * Age 18-50 years. * Moderate-to-severe allergic symptoms upon exposure to dogs. * Dog allergy confirmed by positive specific IgE. * Considered suitable by the investigator for treatment with Alutard SQ Dog in accordance with the approved Summary of Product Characteristics (SmPC). * Female subjects of childbearing potential must use adequate contraception. * A negative pregnancy test must be obtained prior to enrolment. Exclusion Criteria * Pregnancy or breastfeeding. * Autoimmune or connective tissue disease. * Cardiovascular disease. * Hepatic disease. * Renal disease. * Malignancy. * Upper airway disease (e.g., non-allergic sinusitis or nasal polyposis). * Chronic obstructive or restrictive lung disease. * Treatment with medications that may interfere with the immune response. * Previous immunotherapy or chemotherapy. * Significant chronic disease. * Major metabolic disease. * Alcohol or substance abuse. * Mental or cognitive incapacity that may impair compliance with study procedures. * Known or suspected hypersensitivity to the study product. * Suspected or confirmed bacterial infection. * Clinically relevant allergy to house dust mite. * Current dog ownership. * Any condition that, in the investigator's opinion, may make participation, follow-up, or study assessments inappropriate. * Any subject considered unsuitable for enrolment according to the principles of the Declaration of Helsinki.
Conditions Asthma in Children
Phase NA
Enrollment 80
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this randomized control trial is to learn if box fans and filters can reduce asthma symptoms and improve indoor air quality in children ages 6 - 17 years old with asthma living in the Duwamish Valley, Seattle, Washington. The main question it aims to answer are: * Do box fans with filters improve asthma symptoms? * Do box fans with filters improve an objective measure used to monitor lung function known as forced expiratory volume during the first second (FEV1)? Researchers will compare children living in households with high quality filters to those in households with sham filters to see if air quality and asthma symptoms improve. Participants will * fill out several questionnaires * monitor their lung function with a peak flow meter * place an air monitor in their homes to monitor indoor air quality * run the box fan when they are at home

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Double

Interventions / Regimen

  • Other: MERV 13 filter — This is an environmental intervention consisting of a low-cost box fan with a MERV 13 filter placed behind it. The company Lasko makes these fans and other environmental appliances.
  • Other: Sham filter — This is an environmental intervention consisting of a low-cost box fan with a sham filter (MERV 1) placed behind it. The company Lasko makes these fans and other environmental appliances.

Primary Outcomes

  • Asthma symptoms (ACQ will be measured weekly for 6 consecutive weeks, two pre-intervention weeks (before box fans have been given to participant) and four weeks while fans are being used in the home. Symptoms will also be assessed at the six month follow-up visit.)
  • FEV1 (FEV1 measures will be taken daily, once in the morning and once at night for the six week study time frame. Prior to the six month follow up we will ask participants to take three consecutive days of FEV1 measurements, for an additional 6 measures)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-07-30
Completion: 2028-07
Eligibility
Age: 6 Years – 17 Years
Sex: ALL
Volunteers: false
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Washington
Collaborators: National Institute of Environmental Health Sciences (NIEHS)
Principal Investigators:
  • Anjum Hajat, PhD, MPH (PRINCIPAL_INVESTIGATOR) - University of Washington
Contact Information
Study Contact:
Anjum Hajat, PhD, MPH
206-685-3618
anjumh@uw.edu
Joseph Santana, MPH
253-235-9148
joseph@drcc.org
Duwamish River Community Coaltion
Interventions
  • Other: MERV 13 filter — This is an environmental intervention consisting of a low-cost box fan with a MERV 13 filter placed behind it. The company Lasko makes these fans and other environmental appliances.
  • Other: Sham filter — This is an environmental intervention consisting of a low-cost box fan with a sham filter (MERV 1) placed behind it. The company Lasko makes these fans and other environmental appliances.
Study Locations (1 sites)
Duwamish River Community Coaltion, Seattle, Washington 98108 United States
Eligibility Criteria
Inclusion Criteria: * age (6-17 years) * poorly controlled physician diagnosed asthma defined as more than four days with asthma symptoms in the past two weeks, use of asthma rescue medication for more than four days in the past two weeks, or health care utilization due to asthma in the past year (hospitalization, emergency room visit, or unscheduled clinic visit) * living in Georgetown and South Park neighborhoods of Seattle Exclusion Criteria: * children with unstable housing or shared custody arrangements
Conditions Asthma
Phase NA
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

Nocturnal worsening of asthma is common. It is characterized by overnight exacerbation of asthma symptoms such as shortness of breath, chest tightness, coughing, and wheezing, increased need of asthma medications and airway hyperresponsiveness, and decline in lung function (1). Nocturnal asthma has been attributed in part to circadian variations in lung function and airway inflammation. However, other factors including sleep, supine posture and lung volume may also contribute to nocturnal asthma. Current treatments often improve nighttime asthma symptoms. Nevertheless, nocturnal asthma is still common. Up to 2/3rd of asthma patients report nocturnal asthma symptoms, and many asthma related events occur at night, indicating poor asthma control. Results from an ongoing study suggest that in asthma while subjects were supine, fluid shifted out of the legs and accumulated in the thorax (rostral fluid shift) contributing to lower airway narrowing in asthma. A previou study has shown that wearing compression stockings during the day reduces fluid retention in the legs, reduces nocturnal rostral fluid shift out of the legs, and improves sleep apnea (2, 3). The aims of the proposed study is investigate whether off-the-shelf, below the knee compression stockings will attenuate nocturnal fluid shift and lower airway narrowing in asthma.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Other: Compression Stockings — We will use knee length, ready-made compression stockings at a pressure of 20-30mmHg at the ankle and if a good fit cannot be obtained, custom-made stockings will be ordered. Patients will be measured for compression stockings by a certified fitter.
  • Other: Control — Participants will not wearing compression stockings for two weeks.

Primary Outcomes

  • Effect of wearing compression stockings on reducing rostral fluid shift during sleep and its effect in airway narrowing (After 2 weeks of the intervention)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2017-02-21
Completion: 2026-08-31
Eligibility
Age: 20 Years – 75 Years
Sex: ALL
Volunteers: true
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University Health Network, Toronto
Principal Investigators:
  • Azadeh Yadollahi (PRINCIPAL_INVESTIGATOR) - Scientist
Contact Information
Study Contact:
Cristina O Francisco
416 597 3422
cristina.francisco@uhn.ca
Cristina Francisco, PhD
416 597 3422
cristina.francisco@uhn.ca
Toronto Rehabilitation Institute (TRI)
Azadeh Yadollahi, PhD
Toronto Rehabilitation Institute (TRI)
Interventions
  • Other: Compression Stockings — We will use knee length, ready-made compression stockings at a pressure of 20-30mmHg at the ankle and if a good fit cannot be obtained, custom-made stockings will be ordered. Patients will be measured for compression stockings by a certified fitter.
  • Other: Control — Participants will not wearing compression stockings for two weeks.
Study Locations (1 sites)
Toronto Rehabilitation Institute (TRI), Toronto, Ontario M5G 2A2 Canada
Eligibility Criteria
Inclusion Criteria: non-smokers or former smokers (\<10 pack/year) Exclusion Criteria: uncontrolled hypertension
Conditions Asthma Acute
Phase NA
Enrollment 448
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

Asthma is a common chronic bronchial disease affecting 300 million people worldwide. The disease can be severe when it is not managed properly or when it is not controlled by treatments. Asthma is characterized by bronchial inflammation, bronchial hyperreactivity and tissue remodeling. Symptoms include episodes of coughing, dyspnoea and wheezing in relation with bronchial obstruction. The evolution is marked by the occurrence of exacerbations (increase of symptoms), most often triggered by viral infections, mostly due to rhinoviruses. The treatment of asthma is based on inhaled corticosteroid therapy sometimes combined with other treatments that help control the majority of asthma. However, about 10% of patients suffer from persistent symptoms despite these treatments. Natural killer (NK) cells are important actors of the antiviral innate immune response and are present in high numbers in the lungs. However, their role in severe asthma and its virus-induced exacerbations is unknown. The purpose of this work is to characterize NK cells in severe asthma in order to identify molecules expressed differently from control subjects. The goal is to assess whether these molecules could be potential biomarkers of a severe asthma subtype, also known as the endotype, and/or be the molecular control for exacerbation. The advantage of identifying biomarkers for inflammatory diseases lies in their usefulness in establishing a correct diagnosis, monitoring the progress of the disease and the effectiveness of treatments. The secondary objectives are to characterize the activation of NK cells in response to in vitro rhinovirus infection of different types, in monoculture or in a model of interaction with a bronchial epithelium, and identify one or more molecules involved in the interaction between bronchial epithelial cells and NK cells.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Basic Science Masking/blinding: None

Interventions / Regimen

  • Biological: blood sample — Blood sample (56mL) taken in a heparin tube

Primary Outcomes

  • Changes in expression of one or more molecules on the surface of NK cells (day 1 to day 2555)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-09-07
Completion: 2030-09
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 448 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Institut National de la Santé Et de la Recherche Médicale, France
Contact Information
Study Contact:
Pascal Chanez, PU-PH
+334.91.96.58.64
pascal.chanez@univ-amu.fr
Catherine Duez, CRCN
+334.91.32.42.74
catherine.duez@inserm.fr
Pascal CHANEZ, PU-PH
+334.91.96.58.64
pascal.chanez@univ-amu.fr
Hôpital NORD - AP-HM, Clinique des bronches, de l'allergie et du sommeil
Interventions
  • Biological: blood sample — Blood sample (56mL) taken in a heparin tube
Study Locations (1 sites)
Hôpital NORD - AP-HM, Clinique des bronches, de l'allergie et du sommeil, Marseille, 13915 France
Eligibility Criteria
Inclusion Criteria: Cases asthma controlled, uncontrolled excluding exacerbation, uncontrolled asthma exacerbation, and healthy volunteers: * Consent form read, understood, approved and signed before any study procedure * Membership of a social security scheme or beneficiary of such a scheme * Patient aged over 18 Cases asthma controlled, uncontrolled excluding exacerbation, uncontrolled exacerbation: \- Diagnosis of severe asthma confirmed by a respirologist at an expert centre Case asthma controlled: \- Asthma control confirmed by a lung specialist from an expert centre Case uncontrolled asthma excluding exacerbation: \- Uncontrolled asthma confirmed by a lung specialist from an expert centre Case uncontrolled asthma with exacerbation: \- Current exacerbation Exclusion Criteria: Cases asthma controlled, uncontrolled excluding exacerbation, uncontrolled asthma exacerbation, and healthy volunteers: * Person subject to a legal protection measure * Vulnerable population: minors, persons under guardianship or trusteeship or persons deprived of their rights to liberty by court order. * women with a known pregnancy * Inability or refusal to comply with research requirements * Active or weaned smoker \> 15 PA * Treatment with non-steroidal anti-inflammatory drugs (NSAIDs) or opioids in the 10 days prior to inclusion Case patient with asthma: \- Coexistence of a chronic inflammatory disease other than asthma Case healthy volunteers: \- Coexistence of an inflammatory pathology Exclusion criteria: Cases asthma: Pregnancy during follow-up Cases healthy volunteers: Total IgE level greater than 100 kU/L (measured on the study sample)
Conditions Depression, Cancer
Phase NA
Enrollment 86
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

Cancer-related depression (CRD) is a common psychological condition among cancer patients during diagnosis, treatment, and recovery, and is associated with reduced quality of life, impaired immune function, and poorer clinical outcomes. As cancer incidence and mortality continue to rise in China, the psychological burden on patients is receiving increasing attention. Electroacupuncture (EA) has shown potential in treating various types of depression and related somatic symptoms, but evidence regarding its efficacy, safety, and long-term effects in CRD remains limited. This randomized controlled trial aims to evaluate the short- and long-term efficacy and safety of EA for CRD, with the goal of providing evidence to support effective and optimized treatment strategies.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Device: Electroacupuncture treatment — Participants in this group will receive electroacupuncture (EA) based on a semi-standardized protocol. Each treatment session will involve needling at six main acupoints and two supplementary points, selected based on individual symptoms. * Main acupoints: Baihui (GV20), Yintang (EX-HN3), Guanyuan (CV4), Qihai (CV6), bilateral Zusanli (ST36), bilateral Sanyinjiao (SP6). * Supplementary acupoints: Selected from Shenting (GV24), Sishencong (EX-HN1), Fengchi (GB20), Neiguan (PC6), Hegu (LI4), Shenmen (HT7), Yanglingquan (GB34), Taixi (KI3), and Taichong (LR3). All patients will be placed in the supine position. After routine disinfection of all acupoints using 75% alcohol, needles will be inserted using a gentle tapping technique. Once Deqi sensation is achieved, three pairs of electrodes from an EA device will be connected to the handles of the needles at Baihui and Yintang, and bilaterally at Zusanli and Sanyinjiao. Each treatment session will last for 30 minutes.
  • Other: Superficial acupuncture at Non-Acupoints — Participants in this group will receive superficial acupuncture at six pseudo-acupoints that do not correspond to any recognized meridian or traditional acupoint. These points are anatomically matched in location (head, upper limbs, lower limbs, and trunk) to the main acupoints used in the EA group but are located at non-meridian, non-acupoint sites in a horizontal position. Acupuncture needles will be connected to an electroacupuncture device with broken wires and thus no electrical stimulation is actually delivered. All patients will be placed in a supine position. After routine disinfection of the selected sites using 75% alcohol, sterile disposable filiform needles (0.22 × 25 mm) will be lightly inserted to a depth of approximately 3 mm without requiring deqi. The needles will be applied using a gentle tapping technique at non-meridian, non-acupoint locations. The needle will be retained for 30 minutes. The session frequency and total treatment course will match the EA group.
  • Other: Standard care — All participants, regardless of group assignment, will receive standard care as part of routine oncological and psychological management. Standard care includes: * Basic psychological support: General psychological counseling or emotional support provided by nursing staff or clinical psychologists as needed, without structured psychotherapy or pharmacological antidepressant interventions unless clinically indicated. * Health education: Guidance on sleep hygiene, nutrition, and stress management, along with education about cancer-related emotional symptoms and coping strategies. * Medication management: Participants will continue their current medications for chronic comorbidities (e.g., antihypertensives, antidiabetics) as previously prescribed. However, cancer-related medications associated with active treatment-such as chemotherapy, targeted therapies, immunotherapy, or hormonal therapy-will be excluded during the trial period to avoid confounding effects.

Primary Outcomes

  • Hamilton Depression Rating Scale - 17 items (Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-07-01
Completion: 2027-07-01
Eligibility
Age: 18 Years – 75 Years
Sex: ALL
Volunteers: false
Enrollment: 86 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Shanghai Municipal Hospital of Traditional Chinese Medicine
Principal Investigators:
  • Shifen Xu, Doctor (STUDY_DIRECTOR) - SHMTCM's Acupuncture Department
Contact Information
Study Contact:
Xuan Yin, Doctor
86-18939916330
yinxuan0623@hotmail.com
Tao Guo, Master
86-15047856427
guotao2000@126.com
XUAN YIN
Shanghai Municipal Hospital of Traditional Chinese Medicine
Interventions
  • Device: Electroacupuncture treatment — Participants in this group will receive electroacupuncture (EA) based on a semi-standardized protocol. Each treatment session will involve needling at six main acupoints and two supplementary points, selected based on individual symptoms. * Main acupoints: Baihui (GV20), Yintang (EX-HN3), Guanyuan (CV4), Qihai (CV6), bilateral Zusanli (ST36), bilateral Sanyinjiao (SP6). * Supplementary acupoints: Selected from Shenting (GV24), Sishencong (EX-HN1), Fengchi (GB20), Neiguan (PC6), Hegu (LI4), Shenmen (HT7), Yanglingquan (GB34), Taixi (KI3), and Taichong (LR3). All patients will be placed in the supine position. After routine disinfection of all acupoints using 75% alcohol, needles will be inserted using a gentle tapping technique. Once Deqi sensation is achieved, three pairs of electrodes from an EA device will be connected to the handles of the needles at Baihui and Yintang, and bilaterally at Zusanli and Sanyinjiao. Each treatment session will last for 30 minutes.
  • Other: Superficial acupuncture at Non-Acupoints — Participants in this group will receive superficial acupuncture at six pseudo-acupoints that do not correspond to any recognized meridian or traditional acupoint. These points are anatomically matched in location (head, upper limbs, lower limbs, and trunk) to the main acupoints used in the EA group but are located at non-meridian, non-acupoint sites in a horizontal position. Acupuncture needles will be connected to an electroacupuncture device with broken wires and thus no electrical stimulation is actually delivered. All patients will be placed in a supine position. After routine disinfection of the selected sites using 75% alcohol, sterile disposable filiform needles (0.22 × 25 mm) will be lightly inserted to a depth of approximately 3 mm without requiring deqi. The needles will be applied using a gentle tapping technique at non-meridian, non-acupoint locations. The needle will be retained for 30 minutes. The session frequency and total treatment course will match the EA group.
  • Other: Standard care — All participants, regardless of group assignment, will receive standard care as part of routine oncological and psychological management. Standard care includes: * Basic psychological support: General psychological counseling or emotional support provided by nursing staff or clinical psychologists as needed, without structured psychotherapy or pharmacological antidepressant interventions unless clinically indicated. * Health education: Guidance on sleep hygiene, nutrition, and stress management, along with education about cancer-related emotional symptoms and coping strategies. * Medication management: Participants will continue their current medications for chronic comorbidities (e.g., antihypertensives, antidiabetics) as previously prescribed. However, cancer-related medications associated with active treatment-such as chemotherapy, targeted therapies, immunotherapy, or hormonal therapy-will be excluded during the trial period to avoid confounding effects.
Study Locations (1 sites)
Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai, China
Eligibility Criteria
Inclusion Criteria: 1. Presence of depression attributed to cancer itself or cancer-related treatments, meeting the diagnostic criteria for depressive disorder(DSM-V). 2. Age between 18 and 75 years, regardless of sex. 3. Hamilton Depression Rating Scale-17 (HDRS-17) total score \>17 at baseline. 4. Eastern Cooperative Oncology Group (ECOG) performance status score of ≤2. 5. No previous exposure to acupuncture treatment. 6. Ability to understand the study procedures and willingness to provide written informed consent. Exclusion Criteria: 1. Planned to undergo surgery, chemotherapy, radiotherapy, immunotherapy, or other active cancer-related treatments during the study period. 2. History of major depressive episodes prior to cancer diagnosis. 3. Pain Rating Index (PRI) score ≥4 due to cancer-related pain. 4. Estimated life expectancy of 12 months or less. 5. Presence of severe ulcers, abscesses, or active skin infections at or near the acupuncture sites. 6. Clinically significant dysfunction of major organs, including severe cardiac, cerebral, hepatic, renal impairment; decompensated pulmonary disease; or other serious systemic illnesses. 7. Pregnant or breastfeeding women. 8. Participation in another clinical trial within the past 30 days. 9. Patients with a cardiac pacemaker or other implanted electronic medical devices.

Leucine in Midlife Depression

NCT06580145
Recruiting
Conditions Major Depression
Phase PHASE2
Enrollment 75
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

The study aims to investigate the effects of a 6-week leucine challenge on brain chemistry, connectivity, and behavior in people with midlife depression. The researchers will compare the leucine and an active comparator arm (lysine) for 6 weeks.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Drug: L-leucine — L-leucine is an essential amino acid used to competitively inhibit kynurenine uptake into the brain via the large neutral amino acid transporter (LAT1). The proposed dose for L-leucine is 4.31 g/day, administered orally.
  • Drug: L-lysine — L-lysine monohydrochloride is also an essential amino acid. It serves as an active comparator to control for general effects on brain protein synthesis and enters the brain through separate cationic amino acid transporters. The proposed dose for L-lysine is 6 g/day, administered orally

Primary Outcomes

  • Change in Glutamate (Baseline, Week 1, Week 6)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-02-01
Completion: 2029-06
Eligibility
Age: 35 Years – 65 Years
Sex: ALL
Volunteers: false
Enrollment: 75 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Emory University
Collaborators: National Institute of Mental Health (NIMH)
Principal Investigators:
  • Ebrahim Haroon, MD (PRINCIPAL_INVESTIGATOR) - Emory University
Contact Information
Study Contact:
Ebrahim Haroon, MD
(404) 727-8229
eharoon@emory.edu
Diana Beltran, BS
404-712-7686
djbeltr@emory.edu
Ebrahim Haroon, MD
404-712-2890
eharoon@emory.edu
Emory University Hospital
Interventions
  • Drug: L-leucine — L-leucine is an essential amino acid used to competitively inhibit kynurenine uptake into the brain via the large neutral amino acid transporter (LAT1). The proposed dose for L-leucine is 4.31 g/day, administered orally.
  • Drug: L-lysine — L-lysine monohydrochloride is also an essential amino acid. It serves as an active comparator to control for general effects on brain protein synthesis and enters the brain through separate cationic amino acid transporters. The proposed dose for L-lysine is 6 g/day, administered orally
Study Locations (1 sites)
Emory University Hospital, Atlanta, Georgia 30322 United States
Eligibility Criteria
Inclusion Criteria: * Able and willing to provide informed consent * Diagnosis of major depression per Structured Interview for DSM-V (SCID-V) * Moderate to severe depression- Inventory of Depressive Symptoms - Self Reported (IDS-SR score \>34). * SHAPS score \>30 on the 0-56 scale * Body mass index (BMI) between 20-35 kg/m2 * Plasma CRP \>1 mg/L * No contraindications to MRI * Availability of friends or family for transportation after lumbar puncture procedure * Clinically significant findings on EKG * Patient Health Questionnaire (PHQ-9) score greater than 10 * Willingness to adopt contraceptive measures. Persons exempt from contraception requirements are: * Persons assigned male at birth * Persons assigned female at birth who: * have undergone a hysterectomy or bilateral oophorectomy; or * have been naturally postmenopausal for at least 24 consecutive months (i.e., has NOT had menses at any time in the preceding 24 consecutive months) Exclusion Criteria: * Leucine-Specific: * History of maple syrup urine disease * Risk of hypoglycemia (unstable diabetes) * History of vitamin B6 deficiency, relative * Lysine-Specific: * On calcium supplements, relative * History of renal/gall stones (could cleared by a primary care provider) * Cognitive: --Cognitive impairment (MMSE score \&lt;28) * Psychiatric Disorders: * Lifetime diagnosis of psychotic disorders. * Current mania/hypomania. * Substance use disorder in the last 6 months. * Active suicidal ideation: * Psychiatric hospitalization in the past year. * Suicide attempts within the last five years. * Scores \>3 on the Columbia Suicide Severity Rating Scale (C-SSRS) * Binge eating in the absence of mood symptoms increases. * Primary diagnosis of severe DSM-V79 anxiety disorders. * Primary diagnosis of DSM-V PTSD (if severity exceeds major depression). * Primary diagnosis of DSM-V obsessive-compulsive disorders. * Significant personality disorders with multiple hospitalizations or suicide attempts. * Developmental disorders (e.g., ADHD). * Concomitant medications: * Immune-active medications (e.g., non-steroidal anti-inflammatory agents). * Antibiotics and immunizations in the past 2 weeks. * Topical or inhaled steroids within the past week. * Oral/parenteral steroids in the last 6 months. * Supplements that impact the immune system (e.g., omega-3, probiotics) within the past 2 weeks. * Psychotropic medications within the last 4 weeks (8 weeks for fluoxetine). * Daily use of sedative-hypnotics, benzodiazepines, and opiates. * Medical Disorders: * Unstable medical disorders (frequent provider or medication changes). * Lifetime diagnosis/treatment of cancers (excluding basal cell carcinoma). * Lifetime diagnosis/treatment of autoimmune disorders. * Lifetime exposure to chemotherapeutic agents. * MRI Considerations: \-- Location and quantity of metallic objects safe to MR * Concomitant Treatment for Depression: \-- Treatments with antidepressant medications or those with antidepressant effects (dopamine supplements). * Treatment for General Medical Conditions (GMCs): * Stabilized medications are allowed if maintained at the same dose during the trial. * Multiple recent changes in concomitant medications reviewed by the study PI * Population * Pregnant women. * Children. * Prisoners. * Individuals unable to consent
Conditions Depression Chronic, Depression and Quali...
Phase PHASE1
Enrollment 608
Locations 3 sites
Compensation Compensation or reimbursement is mentioned in the public study record; confirm details with the study team.
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to learn if ThIA Suivi, a digital tool for remote monitoring of patients, can improve the care of adults with depression who are followed by a psychiatrist. The main question it aims to answer is: \* Does using ThIA Suivi in addition to usual psychiatric care increase the proportion of patients whose depression symptoms have clearly improved after 3 months, compared with usual care alone? (Improvement is measured with a questionnaire on depression symptoms, the PHQ-9, and is defined as a drop of at least 5 points from the starting score.) Researchers will compare patients who use ThIA Suivi with patients who receive usual care only, to see if ThIA Suivi leads to a greater improvement in symptoms. The researchers' hypothesis is that patients using ThIA Suivi will do better. \[ Participants will: * Continue to be followed by their psychiatrist as usual. * Use ThIA Suivi or will receive usual care only * Complete questionnaires about their symptoms at 3 months, 6 months and 12 months. * Be followed for 12 months. Why is this study needed? Depression is a common mental health condition. It causes lasting sadness, loss of interest in everyday activities, and low energy. About 280 million people worldwide live with depression. It affects daily life, work, and relationships, and it can come back: more than half of people who have one episode will have another. Depression is often treated with antidepressant medication. However, after 8 weeks of treatment, only about 1 in 3 people fully recovers. Side effects can appear before the benefits, which can make it hard to keep taking the medication. Close follow-up after treatment starts is therefore important. In practice, the first follow-up visit often happens late (a median of 27 days after the prescription in France). In addition, psychiatrists are not evenly spread across France, and most first antidepressant prescriptions are written by general practitioners. Digital tools may help patients and health professionals stay in contact between visits. In France, however, no remote monitoring tool for mental health is currently reimbursed by the national health insurance. ThIA Suivi was developed by ThIA Santé Mentale to fill this gap. It is meant to be used within a care pathway supervised by health professionals. The researchers hope that it will improve patients' care, help them stay on track with treatment, and reduce the risk of the depression coming back.

Design

Study type: Interventional Phases: Phase1 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Device: Use of ThIA Medical Device — As soon as the patient has provided free and informed consent, signed it, he or she will be randomized and assigned to one of the two study arms: standard care combined with ThIA Suivi remote medical monitoring, or standard care alone. Regardless of which randomization arm he or she is assigned to, the patient will receive optimal care. The patient in this arm will have access to the "ThIA Suivi" remote medical monitoring system starting the days following their medical consultation with the psychiatrist and throughout his/her participation in the study, in addition to his/her usual standard of care. The patient will have access to all the features of the ThIA Suivi app, including personalized therapeutic education, standardized questionnaires to assess mental health, an alert and notification system, as well as monitoring of side effects and treatment adherence. This system will enable real-time monitoring of symptom progression, allowing the psychiatrist to intervene quickly.

Primary Outcomes

  • Number of Participants with A Reduction of 5 Points in PHQ-9 Score (From enrollment to 6 months after)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2026-04-01
Completion: 2027-09-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 608 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: ThIA Santé Mentale
Collaborators: Digital Medical Hub
Contact Information
Study Contact:
Nicolas Desrumaux, PhD
0033684979459
admin@digitalmedicalhub.com
Jacques Boulet
0033668667725
jacques.boulet@digitalmedicalhub.com
Denis Boucaud-Maître, PhD, HDR
0033400000000
Denis.boucaud-maitre@ch-le-vinatier.fr
Centre Hospitalier Le Vinatier
Interventions
  • Device: Use of ThIA Medical Device — As soon as the patient has provided free and informed consent, signed it, he or she will be randomized and assigned to one of the two study arms: standard care combined with ThIA Suivi remote medical monitoring, or standard care alone. Regardless of which randomization arm he or she is assigned to, the patient will receive optimal care. The patient in this arm will have access to the "ThIA Suivi" remote medical monitoring system starting the days following their medical consultation with the psychiatrist and throughout his/her participation in the study, in addition to his/her usual standard of care. The patient will have access to all the features of the ThIA Suivi app, including personalized therapeutic education, standardized questionnaires to assess mental health, an alert and notification system, as well as monitoring of side effects and treatment adherence. This system will enable real-time monitoring of symptom progression, allowing the psychiatrist to intervene quickly.
Study Locations (3 sites)
Centre Hospitalier Le Vinatier, Bron, 69678 France
Hôpital Novo, Pontoise, 95300 France
Hôpital Uzès - Le Mas Careiron Secteur 30G07 - CMP de Saint Hippolyte du Fort, Uzès, 30700 France
Eligibility Criteria
Inclusion Criteria: * Patients with a PHQ-9 score of ≥ 15 and a confirmed diagnosis of depression * Patients under the care of the investigator; * Patients who have not received any treatment for at least 6 weeks and to whom the investigator prescribes an antidepressant. * Patients with a smartphone, computer or tablet with internet access; * Patients covered by a health insurance scheme; * Patients able to read and understand French; * Patients who have signed a written, informed consent form in person to take part in the study. Exclusion Criteria: * Patients under guardianship, curatorship or judicial protection, or subject to any other administrative or judicial measure resulting in the deprivation of rights and freedoms; * Patients with neurocognitive disorders or psychiatric conditions (e.g. psychotic disorders, cognitive impairments or manic states) that may compromise their ability to give free and informed consent and/or to comply with the study protocol; * Patients at imminent risk of suicide or with severe depression accompanied by psychotic symptoms; * Patients deemed non-autonomous by the psychiatrist, i.e. those who, according to clinical assessment, are unable to manage their daily activities independently or lack sound judgement; * Patients already enrolled in another interventional study * Vulnerable persons as defined in Articles L. 1121-5 to 8 and L. 1122-1-2 of the French Public Health Code are excluded from the study.
Conditions Anxiety Disorders, Depressive Disorder, ...
Phase NA
Enrollment 198
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to test the efficacy of a transdiagnostic Internet-delivered interventions for Romanian adolescents with anxiety and/ or depression. The main questions it aims to answer are: * What is the clinical efficacy of the Internet-delivered intervention? * How accurate is the prediction model in predicting who will respond to treatment? Participants will undergo non-invasive fMRI to measure variability in brain signal as a proxy of the neural systems' adaptability before receiving the intervention, then they will be allocated either to the Internet-delivered intervention or control group.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Behavioral: Transdiagnostic Internet-delivered intervention — The intervention consists of 8 modules based on Rational emotive therapy, delivered via 8 weeks.

Primary Outcomes

  • Internalizing problems (baseline, after 8 weeks of intervention, 6 months follow-up)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-04-01
Completion: 2026-06-30
Eligibility
Age: 13 Years – 17 Years
Sex: ALL
Volunteers: false
Enrollment: 198 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Babes-Bolyai University
Principal Investigators:
  • Costina Poetar, PhD (STUDY_CHAIR) - Babeș-Bolyai University
Contact Information
Study Contact:
Kristoffer Mansson, PhD
+46705803267
nils.mansson@ubbcluj.ro
Costina R Poetar, Ph.D
+ 40743589465
costinapoetar@psychology.ro
Babes-Bolyai University
Costina R Poetar, Ph.D
Babes-Bolyai University
Interventions
  • Behavioral: Transdiagnostic Internet-delivered intervention — The intervention consists of 8 modules based on Rational emotive therapy, delivered via 8 weeks.
Study Locations (2 sites)
Babes-Bolyai University, Cluj-Napoca, 400015 Romania
Babeș-Bolyai University, Cluj-Napoca, 400015 Romania
Eligibility Criteria
Inclusion Criteria: * elevated symptoms of anxiety or depression/ internalizing problems (T score\> 60) at intake (based on Youth self-report completed by adolescents) * primary diagnosis of an anxiety/depressive disorder based on DSM-5 criteria according to ADIS-5-C/P interview * age 13-17 * able to read and understand Romanian language * Currently unmedicated or on stable and adequate doses of medication for at least 6 weeks before treatment onset * Internet access Exclusion Criteria: * severe mental disorder (psychosis, severe depression, bipolar disorder, based on clinical interview) * any condition that interferes with the protocol implementation (e.g., physical illness or sensory impairment that interferes with behavioral tasks such as exposure, behavioral activation, unavailable for the next 3 months), * active suicidal ideation (assessed by child psychiatrist during clinical interview) in the last month * currently following CBT/ psychotherapy for anxiety/depression, in the last 6 months * fMRI incompatible (based on safety questionnaire) * Being diagnosed with an intellectual disability, pervasive developmental disorder, an alcohol and/or substance dependence disorder, reading disabilities (based on clinical interview). * Current treatment with benzodiazepines